<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380132</url>
  </required_header>
  <id_info>
    <org_study_id>Nasha Dx Pilot study</org_study_id>
    <secondary_id>03 464</secondary_id>
    <nct_id>NCT01380132</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Anorectal Application of Dx-gel for Treatment of Anal Incontinence</brief_title>
  <official_title>Safety and Efficacy of Anorectal Application of Dx-gel for Treatment of Anal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether anorectal application of Nasha Dx is safe
      and effective for treatment of anal incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients not fully improved after 1:st injection were offered reinjection after 4-6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response as measured by a 50% reduction in no of incontinence episodes.</measure>
    <time_frame>One year posttreatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>One year posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment</measure>
    <time_frame>One year posttreatment</time_frame>
    <description>Graded by the patient as excellent, good, fair or poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in incontinence episodes</measure>
    <time_frame>One year posttreatment</time_frame>
    <description>Measured relative baseline based on a 4-week diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>One year posttreatment</time_frame>
    <description>Measured with a validated bowel function questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Two years posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment</measure>
    <time_frame>Two years posttreatment</time_frame>
    <description>Graded by the patient as excellent, good, fair or poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in incontinence episodes</measure>
    <time_frame>Two years posttreatment</time_frame>
    <description>Measured relative baseline based on a 4-week diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Two years posttreatment</time_frame>
    <description>Measured with a validated bowel function questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response as measured by a 50% reduction in no of incontinence episodes.</measure>
    <time_frame>Two years posttreatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Anal injection of Nasha Dx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anal injection of Nasha Dx</intervention_name>
    <description>Submucous injection of Nasha Dx 5-10 mm above dentate line</description>
    <arm_group_label>Anal injection of Nasha Dx</arm_group_label>
    <other_name>Solesta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incontinence to loose or solid stool at least once weekly (Millers incontinence score
             6-12).

          -  Age 18-80

          -  Available for follow-up for the duration of the study

          -  Written informed consent.

        Exclusion Criteria:

          -  Sphincter defect visible on anal ultrasound.

          -  Pregnancy.

          -  Rectal prolapse or inflammatory bowel disease.

          -  Recent (within 6 months) anal surgery except for haemorrhoids.

          -  Anorectal sepsis.

          -  Anticoagulant medication or bleeding diathesis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm JR Graf, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inst of Surgical Sciences, Uppsala university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, University Hospital</name>
      <address>
        <city>751 82 Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Danielson J, Karlbom U, Sonesson AC, Wester T, Graf W. Submucosal injection of stabilized nonanimal hyaluronic acid with dextranomer: a new treatment option for fecal incontinence. Dis Colon Rectum. 2009 Jun;52(6):1101-6. doi: 10.1007/DCR.0b013e31819f5cbf.</citation>
    <PMID>19581853</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Olof Nilsson</name_title>
    <organization>Uppsala university</organization>
  </responsible_party>
  <keyword>Fecal incontinence</keyword>
  <keyword>Treatment</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

